Prevention ofvenous thromboembolism [VTE]in patients undergoing elective hip or knee replacement surgery: 10mg OD pc or ac. The first dose should be administered 6-10 hours after surgery when haemostasis has been established. Treatment duration of 5 weeks is recommended for patients undergoing elective hip replacement surgery and 2 weeks for patients undergoing elective knee replacement surgery.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is selective direct factor Xa. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Since it does not inhibit thrombin (activated factor II) it has no effects on platelets
Concomitant treatment with CYP3A4- and P-gp-inhibitors such as azole-antimycotics and HIV protease inhibitors such as ritonavir; with severe renal impairment; below 18 years of age; product affecting haemostasis such as NSAIDs, platelet aggregation inhibitors and other antithrombotic agents.
Hypersensitivity to the active substance or excipient[s]; active bleeding; any bleeding risk; pregnancy; and lactation.
Common: increased GGT; increase in transaminases; anaemia; nausea, post- procedural haemorrhage. Uncommon: increase in: lipase, amylase, blood bilirubin, LDH, alka- line phosphatase, tachycardia, thrombocythaemia, syncope, dizziness, headache, constipation, diarrhoea, abdominal and gastrointestinal pain, dyspepsia, dry mouth, vomiting, renal impair- ment, pruritus; contusion, pain in extremity, wound secretion, haemorrhage.